Monoclonal Ab | Ig type | Patients | Regimen | Overall responserate | Adverse events | Reference |
---|---|---|---|---|---|---|
Obinutuzumab (GA-101) | IgG1 | 21 | Obinutuzumab (Refractory B cell NHL) 1600/800 mg 400/400 mg | 60% 35% | Infusion related reaction, neutropenia, anemia, thrombocytopenia, tumor lysis syndrome | [49] |
28 | G-CHOP (Relapsed or refractory FL) 1600/800 mg 400/400 mg | 94% | Infusion related reaction, neutropenia, neuropathy, infection | [50] | ||
28 | G-FC (Relapsed or refractory FL) 1600/800 mg 400/400 mg | 93% | Infusion related reaction, neutropenia, rash, infection | [50] | ||
PRO131921 | IgG1 | 24 | PRO131921 (Relapsed/refractory B cell NHL) 25 to 800 mg/m2 | 27% | Infusion related reaction, upper respiratory tract infection, neutropenia | [51] |
Ocaratuzumab (AME-133v) | IgG1 | 56 | Ocaratuzumab (Relapsed/Refractory FL) 100 mg/m2 375mg/m2 | 36% | Infusion related reaction, nasopharyngitis, asthenia, lymphopenia, infection | [48] |